Download DNB 2019 June MEDICAL ONCOLOGY MEDICAL ONCOLOGY PAPER 3 Question Paper

Download Diplomate in National Board (DNB) 2019 June MEDICAL ONCOLOGY MEDICAL ONCOLOGY PAPER 3 Previous Question Papers

FINAL EXAM
JUNE 2019
Time: 3 hours
NATIONAL BOARD OF EXAMINATIONS
MEDICAL ONCOLOGY
PAPER-III
Max. Marksz100
Important Instructions:
Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and legib/y.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/f/owcharts wherever appropriate.
Write short notes on:
1 .
a)
b)
c)
a)
b)
c)
a)
b)
a)
b)
c)
a)
b)
c)
a)
b)
0)
Staging of neuroblastoma.
Paraneoplastic syndromes associated with neuroblastoma.
Management of stage IV neuroblastoma.
Treatment of low risk gestational trophoblastic neoplasm.
Mixed Mullerian tumour (carcinosarcoma) of uterus.
Sertoli-Leydig cell tumour of ovary.
How will you evaluate a solitary, large supratentorial brain
SOL in a 60-year-old male presenting with neuro-cognitive
decline?
Management of newly diagnosed primary CNS lymphoma.
Role of autologous PBSCT in Non-Hodgkin?s Lymphoma
(NHL).
Conditioning regimes for autologous PBSCT in NHL.
Acute GVHD (Graft vs Host disease)
Indications of treatment in chronic lymphocytic leukemia
(CLL).
Treatment options in newly diagnosed CLL.
Management of hairy cell leukemia.
How do you approach abdominal mass on 5-year?old child?
Staging of Wilms? tumour.
Management of bilateral Wilms? tumour.
-1.
MED ONCO/J/19/17/III
3+3+4
4+3+3
5+5
3+3+4
3+3+4
4+3+3
P.T.O.
POSSESSION/USE OF CELL PHONES 0R AN Y S UCH ELECTRONIC GADGETS IS NOTPERMITTED INSIDE THE EXAMINA TION HALL.

FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
JUNE 2019
MEDICAL ONCOLOGY
PAPER-III
7. a) WHO classification of Myelodysplastic syndrome (MDS). 4+3+3
b) Prognostic scoring systems in MDS.
0) 5q deletion syndrome.
8. a) Diagnostic criteria for Waldenstrom Macroglobulinemia 3+3+4
(WM).
b) International Prognostic scoring staging system in WM.
0) Treatment of newly diagnosed WM.
9. a) Management of Ph positive ALL. 4+3+3
b) Role of MRD in ALL treatment.
0) Ph like ALL and its management.
10. a) Systemictherapy for medullarythyroid cancer. 4+3+3
b) Management of radioiodine refractory papillary thyroid
carcinoma.
0) Anaplastic thyroid carcinoma.
*************
-2.
POSSESSION/USE OF CELL PHONES 0R AN Y S UCH ELECTRONIC GADGETS IS NOTPERMITTED INSIDE THE EXAMINA TION HALL.